Researchers at Stanford have developed innovative Verteporfin conjugates that considerably enhance the solubility and therapeutic potential of Verteporfin.
Researchers from Stanford developed recombinant polypeptide-cytokine conjugates and methods to induce antigen-specific regulatory T cells (Treg) for the treatment of inflammatory and autoimmune diseases.
The technologies described in this patent address a critically important deficit in the statistical methods available to enable comparison of outcomes measured by flow cytometry or similar, data intensive technologies.
Stanford scientists develop a method for assessing patient risk of developing postsurgical neurocognitive complications using a combination of biomarkers. This method will ensure improved interventions and treatment outcomes.
Stanford researchers developed and patented a multiplexed immunohistochemistry method called multiplexed ion beam imaging (MIBI), which uses antibodies tagged with non-biological elemental isotopes (e.g. rare earth elements) and secondary ion mass spectroscopy.
Stanford researchers have developed a method which can simultaneously observe two positron emitting isotopes using two distinct molecular probes and a modified PET scanner. This system enables the simultaneous observation of two different molecular processes.
Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have developed a method for treating and predicting treatment efficacy of triple negative breast cancer (TNBC).
Inventors at Stanford developed a method to leverage mass cytometry, a type of flow cytometry utilizing mass spectrometry, for the detection of heavy metals in leukocytes from individuals exposed to heavy metals in elevated air pollution.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
Stanford scientists have discovered a novel method for treating neuroendocrine tumors by engineering T cells with Synthetic Notch (SynNotch) circuits that enable precise and durable tumor targeting while overcoming antigen heterogeneity.
Researchers in Dr. Bingwei Lu's lab have identified genes that could serve as therapeutic targets for the treatment of Parkinson's disease (PD). PD is a common neurodegenerative movement disorder affecting 1% of the population over the age 60.
Researchers at Stanford have developed methods to enhance bone healing in diabetic patients, who often suffer from impaired fracture healing due to a deficiency in hedgehog signaling in their skeletal stem cells.
Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have generated a crystal structure for human PD-1 in complex with one of its ligands, PD-L2, for use in small molecule inhibitor design.
Stanford researchers have developed an innovative microfluidic platform, EV-Lev, for the isolation and sorting of extracellular vesicles (EVs) from human plasma.